Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

GLMD

Galmed Pharmaceuticals (GLMD)

Galmed Pharmaceuticals Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:GLMD
DateTimeSourceHeadlineSymbolCompany
25/09/202422:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
25/09/202422:00PR Newswire (US)Galmed publishes Results from Aramchol Phase 3 Open Label part in HepatologyNASDAQ:GLMDGalmed Pharmaceuticals Ltd
21/09/202406:46Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
21/09/202404:18Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
21/09/202404:17Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:GLMDGalmed Pharmaceuticals Ltd
19/09/202421:13Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
19/09/202421:00PR Newswire (US)Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic DiseasesNASDAQ:GLMDGalmed Pharmaceuticals Ltd
17/09/202406:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
17/09/202406:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
10/09/202414:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:GLMDGalmed Pharmaceuticals Ltd
10/09/202406:30Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
31/08/202406:25Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:GLMDGalmed Pharmaceuticals Ltd
31/08/202406:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
29/08/202406:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
28/08/202406:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
11/07/202422:50Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
06/06/202406:16Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
31/05/202406:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
05/04/202408:06PR Newswire (US)Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023NASDAQ:GLMDGalmed Pharmaceuticals Ltd
16/03/202400:00PR Newswire (US)Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver FibrosisNASDAQ:GLMDGalmed Pharmaceuticals Ltd
15/02/202406:14Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
13/02/202408:15Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
30/11/202316:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:GLMDGalmed Pharmaceuticals Ltd
23/11/202308:48Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:GLMDGalmed Pharmaceuticals Ltd
21/11/202308:37Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
21/11/202308:32PR Newswire (US)Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a StudyNASDAQ:GLMDGalmed Pharmaceuticals Ltd
02/11/202307:15Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:GLMDGalmed Pharmaceuticals Ltd
26/09/202322:51Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
26/09/202322:30PR Newswire (US)Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal FibrosisNASDAQ:GLMDGalmed Pharmaceuticals Ltd
23/09/202306:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GLMDGalmed Pharmaceuticals Ltd
 Showing the most relevant articles for your search:NASDAQ:GLMD